Criteria for inclusion

23rd Aug

Criteria for inclusion



Immunocompetent individuals who:

  • Reach the age of 65 or 70 years of age during the period 1 September 2023 and 31 August 2028. These individuals should be vaccinated on or after (but not before) their 65th or 70th birthday
  • Are aged between 70 years and 79 years old on or before 31 August 2023 and have never received a shingles vaccine and either   

     (i) Zostavax® is no longer available or (ii) Zostavax® is not clinically appropriate for the individual

  • Are currently aged 80 years or over, but received a first dose of Shingrix® before turning 80 years old and require a second Shingrix® dose to complete the course before their 81st birthday

Severely immunosuppressed  individuals from 1 September 2023, who:

  • are aged 50 years and above, and meet the definition of severe immunosuppression in the Box in Chapter 28a
  • are aged between 18 and 49 years and receiving a stem cell transplant See Appendix 1 for further information on cohort eligibility



Immunocompetent individuals on or after 1 September 2023 who:

  • have not yet reached their 65th birthday
  • are between 65 to 69 years of age but reached their 65th birthday on or before 31 August 2023; these individuals must wait until they reach their 70th birthday
  • have not yet reached their 70th birthday
  • are 80 years of age or over, except those who have received a partial course of Shingrix® (who are no longer eligible from their 81st birthday)
  • have had their 70th birthday on or before 31 August 2023 and (i) who have not yet been vaccinated against shingles and (ii) do not have a clinical contraindication to Zostavax® and (iii) Zostavax® is still routinely available at the time of assessment (refer to Zostavax® PGD) All individuals who:


  • have had a confirmed anaphylactic reaction to a previous dose of varicella vaccine or to any component of the vaccine
  • are suffering from acute severe febrile illness (the presence of a minor infection is not a contraindication for immunisation
  • have shingles infection with active lesions are pregnant • have already received one dose of Zostavax® or two doses of Shingrix® prior to assessment • have received a dose of Shingrix® in the last 8 weeks

Source PGDUKHSA publications gateway number: GOV-14999 Shingrix® Herpes Zoster Vaccine Patient Group Direction (PGD) Valid from 1st Sept 2023